CompletedNCT05820100
Observational Study to Assess the Reliability and Validity of the MLYMT and MLSDT
Studying OBSOLETE: Inherited retinal disorder
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Nanoscope Therapeutics Inc.
- Principal Investigator
- Dr Samarendra MohantyNanoscope Therapeutics Inc.
- Intervention
- Observational(other)
- Enrollment
- 35 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2023
Study locations (8)
- Nanoscope Clinical Site, Phoenix, Arizona, United States
- Nanoscope Clinical Site, Beverly Hills, California, United States
- Nanoscope Clinical Site, Miami, Florida, United States
- Nanoscope Clinical Site, Fargo, North Dakota, United States
- Nanoscope Clinical Site, Bellaire, Texas, United States
- Nanoscope Clinical Site, McAllen, Texas, United States
- Nanoscope Clincal Site, San Antonio, Texas, United States
- Nanoscope Clinical Site, Arecibo, Puerto Rico
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05820100 on ClinicalTrials.govOther trials for OBSOLETE: Inherited retinal disorder
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07408232A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)Octant, Inc.
- RECRUITINGEARLY PHASE1NCT07063030A Study of LX107 Gene Therapy in AIPL1-IRD PatientsShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- RECRUITINGPHASE1, PHASE2NCT06852963A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001PYC Therapeutics
- RECRUITINGPHASE1NCT06319872The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal DegenerationUniversity of Rochester
- RECRUITINGPHASE1NCT06936787An Open-label, Dose-ascending Study of IGT001 for Retinitis PigmentosaShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- ENROLLING BY INVITATIONNCT07056738Prospective Exploratory Cohort Study on Ganglion Cell Degeneration in Retinitis Pigmentosa PatientsUniversity Medical Center Goettingen
- ACTIVE NOT RECRUITINGPHASE3NCT06388200A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis PigmentosaOcugen
- RECRUITINGPHASE1NCT06455826MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)PYC Therapeutics